# BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

> **NCT00397501** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **OHSU Knight Cancer Institute**

## Conditions studied

- Brain and Central Nervous System Tumors
- Breast Cancer
- Cognitive/Functional Effects
- Drug/Agent Toxicity by Tissue/Organ
- Psychosocial Effects of Cancer and Its Treatment

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** carboplatin
- **DRUG:** methotrexate
- **DRUG:** sodium thiosulfate

## Key facts

- **NCT ID:** NCT00397501
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-10
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** after original approval, IRB closed enrollment; major revisions required to re-open.
- **Last updated:** 2017-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00397501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00397501, "BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00397501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*